JSAM
NTLA icon

J. Safra Asset Management’s Intellia Therapeutics NTLA Stock Holding History

J. Safra Asset Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-11
Closed – – 121
2022
Q4 		$0 Buy
+11
New +$523 ﹤0.01% 118

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

J. Safra Asset Management's NTLA Position: Q1 2023 in Review

J. Safra Asset Management sold out of Intellia Therapeutics (NTLA) in Q1 2023, closing a stake of 11 shares.

J. Safra Asset Management first reported a position in NTLA in Q4 2022 and held it in 1 quarter. The position peaked at $0 in Q4 2022. 290 funds tracked by Wall St. Rank hold NTLA as of Q1 2023.

  • J. Safra Asset Management reported no remaining Intellia Therapeutics position as of Q1 2023 after selling out during the quarter.
  • J. Safra Asset Management sold 11 Intellia Therapeutics shares in Q1 2023.
  • J. Safra Asset Management first reported a position in Intellia Therapeutics in Q4 2022 and held it in 1 quarter.
  • J. Safra Asset Management's Intellia Therapeutics position peaked at $0 in Q4 2022.
  • 290 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2023.

Based on J. Safra Asset Management's 13F filing for Q1 2023, filed 12 May 2023.